Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution.

Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA.

Mol Cell Proteomics. 2007 Dec;6(12):2212-29. Epub 2007 Oct 15.

2.

Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers.

Ackermann BL, Berna MJ.

Expert Rev Proteomics. 2007 Apr;4(2):175-86. Review.

PMID:
17425454
3.

Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics.

Shi T, Su D, Liu T, Tang K, Camp DG 2nd, Qian WJ, Smith RD.

Proteomics. 2012 Apr;12(8):1074-92. doi: 10.1002/pmic.201100436. Review.

4.

Integration of proteomic-based tools for improved biomarkers of myocardial injury.

Gerszten RE, Carr SA, Sabatine M.

Clin Chem. 2010 Feb;56(2):194-201. doi: 10.1373/clinchem.2009.127878. Epub 2009 Dec 18. Review.

5.

Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry.

Bronsema KJ, Bischoff R, van de Merbel NC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 15;893-894:1-14. doi: 10.1016/j.jchromb.2012.02.021. Epub 2012 Feb 21. Review.

PMID:
22426285
6.

IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery.

Shi T, Zhou JY, Gritsenko MA, Hossain M, Camp DG 2nd, Smith RD, Qian WJ.

Methods. 2012 Feb;56(2):246-53. doi: 10.1016/j.ymeth.2011.09.001. Epub 2011 Sep 10. Review.

7.

Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS.

Becker JO, Hoofnagle AN.

Bioanalysis. 2012 Feb;4(3):281-90. doi: 10.4155/bio.11.319. Review.

8.

Complexity reduction of clinical samples for routine mass spectrometric analysis.

Mesmin C, van Oostrum J, Domon B.

Proteomics Clin Appl. 2016 Apr;10(4):315-22. doi: 10.1002/prca.201500135. Epub 2016 Jan 22. Review.

PMID:
26680238
9.

Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients.

Mustafa GM, Larry D, Petersen JR, Elferink CJ.

World J Hepatol. 2015 Jun 8;7(10):1312-24. doi: 10.4254/wjh.v7.i10.1312. Review.

10.

Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics.

Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1229-39. doi: 10.1016/j.jchromb.2008.11.013. Epub 2008 Nov 14. Review.

PMID:
19041286
11.

Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.

Smith JG, Gerszten RE.

Circulation. 2017 Apr 25;135(17):1651-1664. doi: 10.1161/CIRCULATIONAHA.116.025446. Review.

PMID:
28438806
12.

The clinical utility of mass spectrometry based protein assays.

Lassman ME, McAvoy T, Chappell DL, Lee AY, Zhao XX, Laterza OF.

Clin Chim Acta. 2016 Aug 1;459:155-61. doi: 10.1016/j.cca.2016.05.027. Epub 2016 Jun 1. Review.

PMID:
27259466
13.

Considerations when quantitating protein abundance by immunoblot.

McDonough AA, Veiras LC, Minas JN, Ralph DL.

Am J Physiol Cell Physiol. 2015 Mar 15;308(6):C426-33. doi: 10.1152/ajpcell.00400.2014. Epub 2014 Dec 24. Review.

14.

Plasma prefractionation methods for proteomic analysis and perspectives in clinical applications.

Chutipongtanate S, Chatchen S, Svasti J.

Proteomics Clin Appl. 2017 Jul;11(7-8). doi: 10.1002/prca.201600135. Epub 2017 Mar 21. Review.

PMID:
28195677

Supplemental Content

Support Center